Last reviewed · How we verify
Minnelide™Capsules
At a glance
| Generic name | Minnelide™Capsules |
|---|---|
| Sponsor | Minneamrita Therapeutics LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer (PHASE1)
- Minnelide™ Capsules Alone and in Combination With Paclitaxel in Advanced Gastric Cancer (PHASE1)
- A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Minnelide™Capsules CI brief — competitive landscape report
- Minnelide™Capsules updates RSS · CI watch RSS
- Minneamrita Therapeutics LLC portfolio CI